• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry >Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? depression in alzheimer's disease study 2
【24h】

Is sertraline treatment or depression remission in depressed alzheimer patients associated with improved caregiver well being? depression in alzheimer's disease study 2

机译：抑郁症阿尔茨海默氏症患者的舍曲林治疗或抑郁症缓解与照护者的健康状况改善有关吗？阿尔茨海默氏病的抑郁症研究2

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being. Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease in five clinical research sites across the United States. Participants were caregivers of patients enrolled in the Depression in Alzheimer's Disease Study 2 (N = 131). All caregivers received standardized psychosocial support throughout the study. Caregiver outcome measures included depression (Beck Depression Inventory), distress (Neuropsychiatric Inventory), burden (Zarit Burden Interview), and quality of life (Medical Outcomes Study Short Form Health Survey). Results: Fifty-nine percent of caregivers were spouses, 63.4% were women, and 64.1% were white. Caregivers of patients in both treatment groups had significant reductions in distress scores over the 24-week study period, but there was not a greater benefit for caregivers of patients taking sertraline. However, caregivers of patients whose depression was in remission at week 12 had greater declines in distress scores over the 24 weeks than caregivers of patients whose depression did not remit by week 12. Conclusion: Patient treatment with sertraline was not associated with significantly greater reductions in caregiver distress than placebo treatment. Distress but not level of depression or burden lessened for all caregivers regardless of remission status and even more so for those who cared for patients whose depression remitted. Results imply an interrelationship between caregiver distress and patient psychiatric outcomes. (Am J Geriatr Psychiatry 2014; 22:14-24).
机译：目的：我们想评估老年痴呆患者的舍曲林治疗（与安慰剂相比）或12周抑郁症缓解（与非缓解相比）是否与护理者的健康改善有关。方法：我们在美国五个临床研究地点进行了舍曲林治疗阿尔茨海默氏病患者抑郁症的有效性和安全性的随机，双盲，安慰剂对照临床试验。参加者是阿尔茨海默氏病研究2（N = 131）中抑郁症患者的照顾者。在整个研究过程中，所有护理人员均获得了标准化的社会心理支持。照顾者的结局指标包括抑郁（贝克抑郁量表），痛苦（神经精神病学量表），负担（Zarit Burden访谈）和生活质量（医学成果研究简明健康调查）。结果：59％的照顾者是配偶，63.4％是女性，64.1％是白人。在24周的研究期内，两个治疗组患者的照护者的痛苦评分均显着降低，但服用舍曲林的患者的照护者并未获得更大的收益。但是，在第12周时抑郁得到缓解的患者的照护者在24周内的痛苦评分下降比在第12周时抑郁未缓解的患者的照护者下降更大。结论：舍曲林患者治疗并没有显着增加患者的心绞痛缓解率。照顾者比安慰剂困扰。无论照护状态如何，所有护理人员的苦恼程度都不会减轻，但抑郁程度或负担却不会减轻，而照料抑郁症患者的照护者则更是如此。结果暗示照顾者的困扰与患者精神病学结果之间的相互关系。 （Am J Geriatr Psychiatry 2014; 22：14-24）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号